VSV infection, dsRNA, or RNP induces an antiviral response. (A) A549 cells were treated with either vector alone, vector and VSV (MOI of 10), dsRNA, or RNP for 6 h. WCE (50 μg) was analyzed by SDS-7.5% PAGE, transferred to nitrocellulose, and immunoblotted for IRF-3, IRF-3 S396, IRF-1, ISG56, VSV antisera, or actin as indicated. (B) WCE (5 μg) as outlined was used to analyze IRF-3 binding activity by electrophoretic mobility shift assay with the ISRE of the ISG15 probe. Arrows indicate the protein-DNA complexes of IRF-3 and IRF-3/CBP. (C) A549 cells were pretreated with vehicle (ddH2O or DMSO), ribavirin (500 μg/ml), or cycloheximide (100 μg/ml) 30 min prior to RNP treatment as indicated. WCE (30 μg) was analyzed by SDS-7.5% PAGE, transferred to nitrocellulose, and immunoblotted for IRF-3 and ISG56. (D) In vitro transcriptions either alone or coupled to in vitro translation of VSV N cDNA and VSV genome cDNA were transfected into A549 cells and compared to de novo isolated RNP transfection for 6 h. WCE (60 μg) was analyzed by SDS-7.5% PAGE, transferred to nitrocellulose, and immunoblotted for IRF-3 and ISG56 as indicated.